Drug profile of Myezom 2mg
Myezom 2mg is a derivative of pyrazine & boronic acid that behaves as an unpredictable proteasome inhibitor.
Myezom 2mg is available as lyophilized powder which is given as bolus intravenous injection, which is chemically classified as analogue of dipeptide boronic acid containing an anti-neoplastic activity.
Myezom 2mg is a FDA approved product containing active substance known as Bortezomib.
Myezom 2mg is considered as a targeted therapy, majorly used in multiple myeloma & mantle cell lymphoma.
Myezom 2mg are considered as;
Myezom 2mg is a cytotoxic drug, use cautiously.
Prescribing information of Myezom 2mg
The major prescribing information of Myezom 2mg is;
Multiple myeloma therapy: Myezom 2mg is used in this condition
Mantle cell lymphoma therapy: Patients, who are not responding to at least one chemotherapy regimen, should be followed by treated with Myezom 2mg therapy.
Mechanism of Myezom 2mg
Myezom 2mg is an unstable inhibitor of chymotrypsin like activity of 26S proteasome present in human cells.
The degradation of ubiquitinated proteins are induced by 26S proteasome which is a high protein complex.
The intercellular concentration of specific proteins is regulated by proteasome pathway which manages the homeostasis present within the cells.
The prohibition of 26S proteasome impedes this targeted proteolysis; this may affect the multiple signaling cascades within the cells.
The interruption of normal homeostatic mechanism leads to cell lysis.
Following intravenous administration of 1mg/m2 & 1.3mg/m2 doses, causes maximum plasma concentration time after the initial dose were 57 & 112ng/ml. the absorption of Myezom 2mgis occurs in good manner.
Volume of distribution of Myezom 2mg is occurs relatively 498 to 1884L/m2.
Bortezomib is highly bound to human plasma protein by 83%.
The metabolism of Myezom 2mg is majorly induced by human liver microsomes in vivo.
The Bortezomib is metabolized by undergoes oxidation with the help of CYP 450 isoenzymes like 3A4, 2C19, & 1A2.
Deboronation is the major metabolic pathway of Myezom 2mg, which leads to form 2 deboronated metabolites that undergo hydroxylation to various metabolites, which may inactive as 26S proteasome inhibitors.
The terminal half life of Bortezomib is 40 hours to 193 hours.
The total creatinine clearance range of Bortezomib is 102L/hr & 112L/hr, followed by the dose of 1 & 1.3mg/m2.
The route of excretion has not been evaluated.
When to take the Myezom 2mg
Myezom 2mg should be administered as bolus intravenous injection, do not use any other route.
The IV administration of Myezom 2mg should be within a period of 3 to 5 seconds through bolus IV.
It should be administered with or without food.
Dosage regimens of Myezom 2mg
The usual prescribed dose of Myezom 2mgis 1.3mg/m2. The concentration of Bortezomib is 1mg/ml while administrating through IV.
Bortezomib should be used in combination with oral melphalan & oral prednisolone for the period of nine 6 week therapy cycles.
In cycle 1 to 4, the frequency of Bortezomib should be given as a twice weekly.
In cycles 5 to 9, the frequency reduced to once weekly.
Between successive doses of Bortezomib, at least 72 hours should be elapsed.
Before starting the treatment with Myezom, patients must be examining with;
Platelet counts 70 x 109 L, neutrophils counts 1 x 109L
Non hematological toxicity resolved to grade 1.
Dose alteration in combination therapy;
In grade IV toxicity, hematological toxicity, the dose of melphalan should be reduced by 25%.
If counts of platelets are not above 30 x 109L, interrupt the dose of Myezom
Due to toxicity, the consecutive doses of Bortezomib should be interrupting and follows the dose of Myezom 2mgreduced from 1.3mg/m2 to 1mg/m2; from 1mg/m2 to 0.7mg/m2.
In grade III or any severe hematological toxicity: Interrupt the Myezom 2mgtherapy until the toxicity resolved to grade I or 0.
For mantle cell lymphoma & multiple myeloma in relapse state:
Myezom 2mgshould be administered IV as dose of 1.3mg/m2 for 2 weeks as twice weekly day 1.4.8 & 11 followed by 10 day rest period days 12 to 21.
For prolonged therapy, more than 8 cycles Bortezomib should be given as IV as standard dose for 4 weeks as once a week followed by 13 days rest period days 23 to 35.
Dose alteration in peripheral neuropathy:
Grade I toxicity: no dosage adjustment should be required
Grade I with pain or grade II: The dose of Myezom 2mgshould be reduced to 1mg/m2
Grade II with pain or grade III: Interrupt the treatment til the toxicity changes to grade I or 0.
Grade IV: Stop the treatment.
Dose alteration in liver impairment:
In mild condition: No alteration occurs
In moderate to severe: The dose reduced to 0.7mg/m2 on first cycle, then dose increased to 1mg/m2 or further reduction is required to 0.5mg/m2 based on patients tolerability.
Reconstitution of Myezom 2mg:
Myezom 2mg vial containing 2mg lyophilized powder of Bortezomib as an active substance.
The Myezom 2mg content should be reconstituted by using 2ml of 0.9% of sodium chloride solution.
It is single use vial, the remaining portion of Myezom 2mg solution should be discarded after use.
In this 2ml solution containing 2mg of drug; 1mg/ml
Myezom 2mgcaused side effects
The following adverse effect are most probably occurs during the Myezom 2mg therapy;
Thrombocytopenia or neutropenia
Tumor lysis syndrome
Posterior reversible encephalopathy syndrome
Some common side effects;
Loss of appetite
Post marketing reports;
Multifocal leukoencephalopathy syndrome
Acute diffuse infiltrative pulmonary disease
Drug- drug interaction
Avoid combination of Myezom 2mg with strong CYP3A4 inducers; this combination may produce depletion of exposure of Bortezomib. This concludes as loss of therapeutic effect. Example for strong CYP3A4 inducers is st. Johns wort.
Concurrent use of dexamethasone does not produce any effect on exposure of Bortezomib.
Concurrent use of melphalan prednisolone with Myezom 2mg has no effect on exposure of Bortezomib.
Co administration of Myezom 2mg with strong CYP3A4 inhibitors causes adverse effects related to Bortezomib, because of increasing the exposure of Bortezomib. To overcome the problem, the dose of Myezom 2mg should be reduced.
Food drug interaction
Vitamin C, an ascorbic acid leads to reduce the effectiveness of Bortezomib.
During multiple myeloma treatment, some food should not be taken,
Uncooked meats, seafood
Vitamin & mineral supplements should be used cautiously during Myezom 2mgtherapy.
Myezom 2mg should not be administered through intrathecal route, some fatal events may occur.
Anaphylactic reactions may occur while patients may contraindicate to the component present in Myezom 2mg injection.
Cardiac toxicity: Acute aggravation of congestive heart failure or new commencement of decreased left ventricular ejection may occur during the therapy.
This may leads to QT prolongation
To overcome the problems, patients must be
Monitor with ECG
Provide with general supportive therapy
Discontinue with treatment
Pulmonary toxicity: In a trial period, patient receiving high dose of cytarabine with daunorubicin & Bortezomib should be suggested for acute myelogenous leukemia died for the reason of acute respiratory distress syndrome.
To avoid the problems, therapy should be postponed until the adverse will recovered.
Posterior reversible encephalopathy syndrome: Analysis the patient whether suspected with pulmonary toxicity or not.
Provide with supportive measures
Discontinue the treatment, if disease progression persists.
Gastrointestinal toxicity: Fluid & electrolyte replacement should be given to the patients.
Hematological toxicity: Check the blood cell counts during or before the treatment starts.
Tumor lysis syndrome: patient with high tumor burden before the treatment may suspected highly with tumor lysis syndrome. Monitor the patients by giving appropriate precautions.
Liver toxic: Monitor AST, ALT, bilirubin & other liver enzymes frequently in both before & during the therapy time.
Embryo fetal toxicity: Myezom 2mgis contraindicated to pregnancy and lactation period.
Peripheral neuropathy: Patients may suffered with some grade II or III toxicity during the therapy of Myezom, in this conditions patient should be examine with the symptoms associated to toxicity.
For avoiding this adverse, dose reduction is required and maintains the toxicity grade level to I or 0.
Provide supportive treatment or discontinue the therapy with Myezom.
Hypotension: The hypotension occurrence should be happens during the treatment of MM or MCL with Myezom.
If patient with history of syncope, Myezom 2mg should be used carefully in this patient. The management of postural hypotension may include as anti-hypertensive drugs, hydration, providing with mineralocorticoids or sympathomimetics.
Pregnancy and lactation
Pregnancy category D
Myezom 2mg should not be used in pregnancy condition, causes embryo fetal damage
Myezom 2mg should not be allowed for lactating women, metabolites are present in human milk.
The potency of Bortezomib has not been evaluated in pediatric patients.
Renal damage patients: Dialysis should diminish the concentration of Bortezomib; no dosage adjustment is required for renal insufficiency patients.
Bortezomib treatment should not be preferred on dialysis period; it must be used after dialysis procedure.
The initial dose of Bortezomib is reduced in case of moderate & severe hepatic impaired patients.
In diabetic patients, who are receiving oral anti-diabetic medications should be use Bortezomib carefully by monitoring blood glucose levels frequently.
Dose adjustment of anti-diabetic medication should be necessary.
Storage and handling
The unopened vial should be stored at 20oC to 25oC excursion between 15oC to 30oC.
Protect from moisture, heat & light.
The missed dose should be avoided. If patient missed the cycles, must consult with medical oncologist.
The over dose of Myezom 2mg causes acute commencement of symptomatic hypotension and thrombocytopenia.
For over dose condition, the manifestation should be monitored frequently.
Provide preventive and supportive measures for over dosage of Myezom.